BeStock  
Stocks › Biotechnology › MNPR

Monopar Therapeutics MNPR

US equityMarket cap rank #3666Biotechnology
$83.78 +$4.21 (+5.29%)
Pre-market · Oct 8, 8:20 am ET · After hours $83.80 +0.02%
Open$78.28
Prev close$79.57
Day range$77.98 – $85.03
Volume107.1K
Market cap$562.35M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership109.1%-0.18 pts vs. prior quarter
Institutions holding114+1 vs. prior quarter
Insider trades (recent)31 buys / 19 sellsNet buying
Short interest12.58% of floatDays to cover 7.2 · as of 15 Sep 2026
Short-sale volume share12.9%5-day average of daily volume

Short-sale volume as % of daily volume

8%11%14%16%Sep '26Sep '26Oct '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$711.2K (10 inflow days, 10 outflow days).

Net flow by order size, last 20 sessions

−$730.1KSuper+$18.9KBig−$392.6KMid+$1.2MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 50.9% of shares outstanding.

Largest holders

  • Janus Henderson Group plc19.55%
  • RA Capital Management, L.P.9.94%
  • Tactic Pharma LLC8.46%
  • AstraZeneca PLC7.79%
  • BlackRock5.20%
  • Deerfield Management Company, L.P.4.82%
  • Saturn V Capital Management LP4.65%
  • Artal Group S.A.4.02%

By investor type

  • Mutual Fund47.10%
  • Hedge Fund24.02%
  • VC/PE Fund20.69%
  • Private Company8.64%
  • Public Company8.44%
  • Individual/Insider7.26%
  • Government Pension Fund0.14%
  • Insurance Company0.09%

Reported short interest has fallen from 22.69% to 12.58% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Chandler Robinson Individual/Insider 2026/Q3 +5,457 2.5%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +5,980 0.1%
OrbiMed Advisors LLC VC/PE Fund 2026/Q3 +157,423 2.3%
Candriam, Société En Commandite Par Actions Mutual Fund 2026/Q3 +143,339 2.1%
TCG Crossover Management, LLC VC/PE Fund 2026/Q3 +71,224 3.0%
Longaeva Partners L.P. Mutual Fund 2026/Q3 +55,834 0.8%
Driehaus Capital Management LLC Mutual Fund 2026/Q3 +50,884 1.3%
Ikarian Capital, LLC Hedge Fund 2026/Q3 +47,861 0.7%
BlackRock Mutual Fund 2026/Q3 +32,252 5.2%
StemPoint Capital LP Hedge Fund 2026/Q3 +30,125 0.4%
Boothbay Fund Management, LLC Hedge Fund 2026/Q3 +14,689 0.2%
Neuberger Berman Investment Advisers LLC Mutual Fund 2026/Q3 +12,760 0.8%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +12,660 1.7%
Ishara Investments, L.P. Hedge Fund 2026/Q3 +12,300 0.2%
Trexquant Investment LP Hedge Fund 2026/Q3 +12,004 0.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
30 Sep 2026 Christopher Starr Independent Executive Chairman of the Board Derivative Exercise and Sale -8,400 $79.67 15,053
29 Sep 2026 Andrew Cittadine Chief Operating Officer Derivative Exercise and Sale -1,944 $79.67 58,054
29 Sep 2026 Andrew Cittadine Chief Operating Officer Derivative Exercise and Retained +2,440 – 58,054
29 Sep 2026 Chandler Robinson Chief Executive Officer Derivative Exercise and Sale -4,344 $79.67 167,539
29 Sep 2026 Chandler Robinson Chief Executive Officer Derivative Exercise and Retained +5,457 – 167,539
29 Sep 2026 Quan Vu CFO, Principal accounting officer & Principal financial officer Derivative Exercise and Sale -180 $79.67 2,655
29 Sep 2026 Quan Vu CFO, Principal accounting officer & Principal financial officer Derivative Exercise and Retained +434 – 2,655
23 Sep 2026 Chandler Robinson Chief Executive Officer Derivative Exercise and Sale -29,056 $89.79 162,082
25 Aug 2026 Patrice Rioux Acting Chief Medical Officer Derivative Exercise and Sale -1 $111.26 5,065
25 Aug 2026 Patrice Rioux Acting Chief Medical Officer Other Derivative Acquisition +1,380 $0.01 –
25 Aug 2026 Patrice Rioux Acting Chief Medical Officer Derivative Exercise and Retained +1,379 $0.01 5,065
25 Aug 2026 Kim Tsuchimoto CFO, Secretary, Treasurer & Director Automatic Disposition -4,090 $113.84 11,486
25 Aug 2026 Kim Tsuchimoto CFO, Secretary, Treasurer & Director Derivative Exercise and Sale -4,090 $113.84 11,486
25 Aug 2026 Kim Tsuchimoto CFO, Secretary, Treasurer & Director Other Derivative Acquisition +4,090 $30.00 8,140
24 Aug 2026 Raymond Anderson Independent Director Derivative Exercise and Sale -3,142 $113.05 5,373
24 Aug 2026 Raymond Anderson Independent Director Other Derivative Acquisition +3,142 $30.00 3,480
7 Jul 2026 Arthur Klausner Independent Director Intent to Sell (Form 144) -5,000 – –
29 Jun 2026 Andrew Cittadine Chief Operating Officer Derivative Exercise and Sale -2,309 $92.59 55,614
29 Jun 2026 Andrew Cittadine Chief Operating Officer Derivative Exercise and Retained +2,945 – 55,614
29 Jun 2026 Chandler Robinson Chief Executive Officer Derivative Exercise and Sale -4,084 $92.59 162,082

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
15 Sep 2026 844,226 12.6% 7.2
31 Aug 2026 852,425 12.7% 4.5
14 Aug 2026 887,188 13.2% 3.5
31 Jul 2026 1,065,108 15.9% 3.4
15 Jul 2026 1,360,286 20.3% 5.9
30 Jun 2026 1,519,701 22.7% 8.6

Discussion

No comments yet — be the first to weigh in on MNPR.

Leave a comment

Scroll to Top